Pharmacogenomics and personalized medicine in clinical practice

Pharmacogenomics

Volumn 12, Issue 5, 2011, Pages 597-610

  Manolopoulos, Vangelis G ^a   Dechairo, Bryan ^b   Huriez, Alain ^c   KüÃhn, Alexander ^d   Llerena, Adriãn ^e   Van Schaik, Ron H ^f   J Yeo, Kiang Teck ^g   Ragia, Georgia ^a   Siest, Gerard ^h  

^a DEMOCRITUS UNIVERSITY OF THRACE MEDICAL SCHOOL   (Greece)

^b Medco Health Solutions Inc   (United States)

^c European Personalized Medicine Diagnostics (EPEMED)   (France)

^d MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^e UNIVERSITY OF EXTREMADURA   (Spain)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF CHICAGO   (United States)

^h UNIVERSITÉ DE LORRAINE   (France)

Author keywords

biomarkers; cytochromes; personalized medicine; pharmacogenetics; pharmacogenomics; theranostics

Indexed keywords

ACENOCOUMAROL; ANTINEOPLASTIC AGENT; ATORVASTATIN; CLOPIDOGREL; CYCLOSPORIN; CYTOCHROME P450 2C9; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYCOPHENOLIC ACID; NEUROLEPTIC AGENT; PHENPROCOUMON; TACROLIMUS; WARFARIN;

CANCER GENETICS; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CYP2C9 GENE; DNA POLYMORPHISM; DRUG DOSE ESCALATION; DRUG MEGADOSE; GENE; GENETIC VARIABILITY; GENOTYPE; GRAFT REJECTION; GREECE; HUMAN; LOW DRUG DOSE; MEDICAL EDUCATION; MEDICAL SOCIETY; NEPHROTOXICITY; PATIENT COMPLIANCE; PATIENT SELECTION; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHENOTYPE; REIMBURSEMENT; THROMBOEMBOLISM; TREATMENT RESPONSE; VKORC1 GENE;

CLINICAL TRIALS AS TOPIC; DRUG INDUSTRY; GREECE; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS;

EID: 79957641515     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.14     Document Type: Conference Paper

References (9)

1. Wierling C, Herwig R, Lehrach H: Resources, standards and tools for systems biology. Brief. Funct. Genomic Proteomic. 6(3), 240-251 (2007). (Pubitemid 351863879)
2. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100, 57-70 (2000). (Pubitemid 30046295)
3. Epstein RS, Moyer TP, Aubert REet al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J. Am. Coll. Cardiol. 55(25), 2804-2812 (2010).
4. Mega JL, Close SL, Wiviott SDet al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360, 354-362 (2009).
5. Iakoubova OA, Tong CH, Rowland CMet al. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J. Am. Coll. Cardiol. 51, 435-443 (2008).
6. Thervet E, Loriot MA, Barbier Set al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin. Pharmacol. Ther. 2010 87(6), 721-726 (2010).
7. van Gelder T, Silva HT, de Fijter JWet al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fxed-dose concentration-controlled trial. Transplantation 86(8), 1043-1051 (2008).
8. van Schaik RH, van Agteren M, de Fijter JWet al. UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. Clin. Pharmacol. Ther. 86(3), 319-327 (2009).
9. van Schie RM, Wadelius MI, Kamali Fet al. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 10(10), 1687-1695 (2009).